ReviewReviews in medical virology2010
CMV in critically ill patients: pathogen or bystander?
Review in Reviews in medical virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Does treatment with antiviral medication affect mortality among immunocompetent individuals with cytomegalovirus reactivation? A systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Pooled it
- Trial
- Cytomegalovirus DNAemia as a prognostic marker in critically ill hematopoietic stem cell transplant recipients with lower respiratory tract infection.BMC anesthesiology · 2026Article
- Application Value of Metagenomic Next-Generation Sequencing Using Bronchoalveolar Lavage Fluid and Blood Samples in Patients with Severe Pneumonia Complicated with Bloodstream Infection.Polish journal of microbiology · 2026Article
- Characterization of multiple herpes viremia via next-generation sequencing in patients with lower respiratory tract infections: a retrospective cohort study.BMC infectious diseases · 2026Article
- Lung NK cells are sufficient to control viral dissemination during respiratory MCMV infection.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Cytomegalovirus reactivation and acute and chronic complications in children with cerebral malaria: a prospective cohort study.Malaria journal · 2025Article
- Monitoring Immune Dysfunction in Critically Ill Patients with Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Reactivation of Epstein-Barr virus among intensive care patients: a prospective observational study.Intensive care medicine · 2024Observational
- The diagnostic value of metagenomics next-generation sequencing in HIV-infected patients with suspected pulmonary infections.Frontiers in cellular and infection microbiology · 2024Article
- A high CMV-specific T cell response associates with SARS-CoV-2-specific IL-17 T cell production.Medical microbiology and immunology · 2023Article
- Cytomegalovirus Viremia Predicts Postdischarge Mortality in Kenyan HIV-Exposed Uninfected Children.The Journal of infectious diseases · 2022Article
- The Association of Cytomegalovirus IgM and Allostatic Load.Diseases (Basel, Switzerland) · 2022Article
- Reactivation of EBV and CMV in Severe COVID-19-Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients.Journal of intensive care medicine · 2022Article
- Concurrent and Subsequent Co-Infections ofMicroorganisms · 2022Review
- Cytomegalovirus Viremia and Clinical Outcomes in Kenyan Children Diagnosed With Human Immunodeficiency Virus (HIV) in Hospital.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Observational
- Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice.Vaccines · 2021Review
- 'Lipo-tourism' gone wrong: blood transfusion-transmitted cytomegalovirus disease.BMJ case reports · 2021Article
- EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Despite broad variability in study populations, methodologies for CMV detection, and analytic methods used, multiple studies have documented frequent CMV infection in non-immunocompromised adults with critical illness due to a variety of causes. Higher rates of CMV infection in studies of seropositive patients suggest that reactivation of latent infection rather than primary infection is the main mechanism in this setting. Risk factors for CMV reactivation (other than seropositivity) have not been clearly defined and there does not appear to be a consistent association with severity of illness. Furthermore, CMV reactivation in this setting has been associated with important adverse clinical outcomes, including increased duration of mechanical ventilation, longer length of stay and all-cause mortality. There are several biologically plausible mechanisms that could link CMV reactivation with adverse outcomes, including: direct lung injury (CMV pneumonia), amplification of inflammation systemically and within the lung, or predisposition to other nosocomial infections, but clinical data in the ICU setting are limited. Further observational studies are unlikely to significantly advance our understanding of the role of CMV in critically ill patients. Given the significant impact of critical illness, limited current therapeutic options, the availability of generally well-tolerated antiviral options for CMV, and the clinical data supporting a possible pathogenic role for CMV, there is a strong rationale for a randomised controlled trial of CMV prevention as a novel means of improving the outcomes of critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.